Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in active primary Sjogren's Syndrome
NCT07642843Phase 1Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gamgertamig in primary Sjögren's syndrome, sponsored by Keymed Biosciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 52 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT07642843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07642843.